Exploring the Impact of Model-Informed Precision Dosing on Procalcitonin Concentrations in Critically Ill Patients: A Secondary Analysis of the DOLPHIN Trial

• Published in: Pharmaceutics Vol. 16; no. 2; p. 270
• Main Authors: Dräger, Sarah, Ewoldt, Tim M J, Abdulla, Alan, Rietdijk, Wim J R, Verkaik, Nelianne, Ramakers, Christian, de Jong, Evelien, Osthoff, Michael, Koch, Birgit C P, Endeman, Henrik
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.02.2024; MDPI
• Subjects: Analysis; Antibiotics; biomarker; Biomarkers; critically ill; Drug dosages; Ethylenediaminetetraacetic acid; Health aspects; Infection; Infections; inflammation; Marine mammals; model-informed precision dosing; Pathogens; Patients; Pharmacodynamics; Pharmacokinetics; Population; procalcitonin; Sepsis; Software; Netherlands; inflammation; model-informed precision dosing; procalcitonin; biomarker; critically ill; antibiotics; pharmacodynamic target attainment
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics16020270

Model-informed precision dosing (MIPD) might be used to optimize antibiotic treatment. Procalcitonin (PCT) is a biomarker for severity of infection and response to antibiotic treatment. The aim of this study was to assess the impact of MIPD on the course of PCT and to investigate the association of PCT with pharmacodynamic target (PDT) attainment in critically ill patients. This is a secondary analysis of the DOLPHIN trial, a multicentre, open-label, randomised controlled trial. Patients with a PCT value available at day 1 (T1), day 3 (T3), or day 5 (T5) after randomisation were included. The primary outcome was the absolute difference in PCT concentration at T1, T3, and T5 between the MIPD and the standard dosing group. In total, 662 PCT concentrations from 351 critically ill patients were analysed. There was no statistically significant difference in PCT concentration between the trial arms at T1, T3, or T5. The median PCT concentration was highest in patients who exceeded 10× PDT at T1 [13.15 ng/mL (IQR 5.43-22.75)]. In 28-day non-survivors and in patients that exceeded PDT at T1, PCT decreased significantly between T1 and T3, but plateaued between T3 and T5. PCT concentrations were not significantly different between patients receiving antibiotic treatment with or without MIPD guidance. The potential of PCT to guide antibiotic dosing merits further investigation.